Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775469 | 0.84 | MAPT (0.39) | HTR6MAPTHTR2CMAOA | |
| SCHEMBL29956127 | 0.83 | ENPP2 (0.40) | MAOA | |
| SCHEMBL6770024 | 0.79 | HTR6 (0.39) | HTR6CHRM1 | |
| SCHEMBL5657045 | 0.77 | MAOB (0.31) | MAOBMAOA | |
| SCHEMBL7503453 | 0.74 | MAPT (0.45) | HTR6MAPTALDH1A1HTR2CUSP2 | |
| SCHEMBL28091868 | 0.73 | SMN1; SMN2 (0.34) | MAOB | |
| SCHEMBL21358891 | 0.72 | MAPT (0.37) | HTR6MAPTALDH1A1HTR2C | |
| SCHEMBL336837 | 0.70 | HTR2A (0.45) | HTR6MAPTHTR2C | |
| SCHEMBL28696615 | 0.70 | LMNA (0.40) | MAOBALDH1A1 | |
| SCHEMBL28696616 | 0.70 | ALDH1A1 (0.34) | HTR6MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686355-B2 | TREATING HEART DISEASE, MULTIPLE SCLEROSIS, ARTHRITIS, ATHEROSCLEROSIS, AND OSTEOPOROSIS; ANTICANCER AGENTS | WARNER-LAMBERT COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20020156074-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1233016-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156074-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | MMP3, MMP9, MMP13 | HTR6 2716/4885MAOB 1931/4885MAPT 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.